Evaluating Safety of Escalating Doses of Tilmanocept by IV Injection and SPECT Imaging in Subjects With and Without RA
Clinical trial NCT02865434 · COMPLETED
Trial details
- NCT number
- NCT02865434
- Sponsor
- Navidea Biopharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-01-01
- Primary completion
- 2018-06-01
- Enrollment
- 39
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.